Acute myeloid leukaemia trials in China

In China 226 Also abroad 763

226 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Where
Shenzhen
Age
18 years to 70 years
People
10
Run by
Shenzhen University General Hospital
See details and how to joinNCT07563179
Phase 1Taking people
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Where
Hangzhou
Age
18 years to 75 years
People
25
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06696846
Phase 1/2Taking people
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan, Zhengzhou
Age
18 years and over
People
682
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT04501120
Phase 3Taking people
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Where
Hanzhou
Age
18 years and over
People
324
Run by
Sunshine Lake Pharma Co., Ltd.
See details and how to joinNCT05586074
Phase 2Taking people
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
Where
Suzhou
Age
15 years to 65 years
People
48
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06816134
Phase 2/3Enrolling by invitation
VEN+IDAC vs IDAC in AML
Where
Guangzhou
Age
18 years to 65 years
People
232
Run by
Guangdong Second Provincial General Hospital
See details and how to joinNCT07537257
No phaseTaking people
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
Where
Beijing
Age
6 years to 60 years
People
210
Run by
Peking University People's Hospital
See details and how to joinNCT07537738
No phaseTaking people
The Efficacy of Allo-HSCT in ND HR-CBF-AML
Where
Shanghai
Age
18 years to 65 years
People
90
Run by
Ruijin Hospital
See details and how to joinNCT06458244
No phaseTaking people
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
Where
Suzhou
Age
50 years and over
People
30
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07500753
Phase 3Not yet taking people in China
VAH vs VA in Newly Diagnosed Elderly AML
Where
Shanghai
Age
60 years to 75 years
People
308
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07469046
Phase 1/2Taking people
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Where
Shenzhen
Age
18 years to 75 years
People
96
Run by
Beijing Biotech
See details and how to joinNCT07523555
No phaseNot yet taking people in China
ABC Maintenance Therapy for AML
Where
Wuhan
Age
18 years to 80 years
People
104
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07521124
Phase 2Taking people
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
Where
Beijing
Age
18 years to 70 years
People
48
Run by
Beijing 302 Hospital
See details and how to joinNCT07514832
Phase 2Taking people
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
Where
Beijing
Age
14 years to 60 years
People
204
Run by
Chinese PLA General Hospital
See details and how to joinNCT07512700
Phase 2Taking people
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Where
Beijing
Age
14 years to 75 years
People
200
Run by
Chinese PLA General Hospital
See details and how to joinNCT06084819
Phase 2Not yet taking people in China
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
Where
Hangzhou
Age
18 years and over
People
61
Run by
First People's Hospital of Hangzhou
See details and how to joinNCT07507825
Phase 2Not yet taking people in China
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
Where
Hangzhou
Age
18 years to 75 years
People
35
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07505160
No phaseTaking people
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Where
Beijing
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07500441
Phase 4Taking people
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Where
Beijing
Age
14 years to 75 years
People
200
Run by
Chinese PLA General Hospital
See details and how to joinNCT07101588
Phase 3Taking people
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Where
Shanghai, Suzhou
Age
14 years to 70 years
People
594
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07463651
Phase 3Not yet taking people in China
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
Where
Changzhou, Hangzhou, Hefei, Huai'an, Jinan, Jingjiang, Lianyungang, Luoyang, Nanjing, Nantong, Ningbo, Suzhou, Wuhan, Wuxi, Yancheng, Yangzhou
Age
18 years to 65 years
People
204
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07486479
Phase 1/2Not yet taking people in China
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Where
Shanghai
Age
18 years and over
People
112
Run by
Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07486726
Phase 2Taking people
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Where
Suzhou
Age
18 years to 80 years
People
32
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06220162
No phaseNot yet taking people in China
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
Where
Hangzhou, Ningbo
Age
1 year to 21 years
People
400
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07483749
Phase 1/2Taking people
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
Where
Suzhou
Age
18 years and over
People
29
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07451912